Wednesday, January 3, 2024

Radionetics Oncology Snags $52.5M

San Diego-based Radionetics Oncology, a company that is working on cancer treatments, said this morning that it has raised $52.5M in a Series A funding. The funding was led by Frazier Life Sciences, 5AM Ventures and DCVC Bio. According to Radionetics, it has now raised a total of $82.5M in total funding. As part of the funding, it has named Paul Grayson as CEO of the company, and added Eric Shiozaki of DCVC Bio to its board of directors. Radionetics says it plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers. Grayson was most recently President and CEO of Tentarix Biotherapeutics, and was a founder at Fate Therapeutics, BirdRock Bio, SEnomyx, and Aurora Biosciences.